Company summary
Genus is an animal-genetics company supplying breeding technology to pig and cattle producers. Its PIC business focuses on porcine genetics while ABS provides bovine genetics, reproductive technology and related services.
← Back to the 350
GNS
Genus
Pharmaceuticals & Biotechnology
- Index
- FTSE 250
- ISIN
- Not specified
- Book status
- 2026 edition — current
Key activities
Pig and cattle genetics, semen and embryo technologies, breeding programmes, genomic selection, reproductive services and development of gene-edited disease-resistant animals.
Key markets
Global livestock markets, with substantial operations across North America, Latin America, Europe and Asia, including an important presence in China.
Key drivers
Livestock producer profitability, genetic-market share, growth in China and Latin America, ABS volumes, royalty streams, successful commercialisation of disease-resistant genetics and operating efficiency.
Key risks
Livestock disease outbreaks, agricultural cycles, regulatory approval of gene-edited animals, Chinese market volatility, currency movements, research costs and slow adoption of new genetics.
Recent Developments
14 July 2026: Genus said FY2026 adjusted pre-tax profit was expected to be around £98m, ahead of previous expectations. PIC performed strongly in Asia and Latin America, ABS delivered double-digit profit growth and commercial progress continued on PRRS-resistant pigs.
Dividend notes
Pays interim and final dividends. The FY2026 interim dividend was 11.2p, went ex-dividend on 5 March and was paid on 27 March. The full-year dividend will be set with September results.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.